Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques

Journal of Virology

Volumn 84, Issue 12, 2010, Pages 5898-5908

  Rosario, Maximillian ^a   Hopkins, Richard ^a   Fulkerson, John ^b   Borthwick, Nicola ^a   Quigley, Máire F ^c   Joseph, Joan ^d   Douek, Daniel C ^c   Greenaway, Hui Yee ^e   Venturi, Vanessa ^e   Gostick, Emma ^f   Price, David A ^c,f   Both, Gerald W ^g   Sadoff, Jerald C ^b   Hanke, Tomáš ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Aeras Global TB Vaccine Foundation   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d UNIVERSITY OF BARCELONA   (Spain)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^g Riverside Life Sciences Building   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BCG HIVA 401 VACCINE; BCG VACCINE; GAMMA INTERFERON; HIVA ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; MVA HIVA VACCINE; OADV HIVA VACCINE; TUBERCULIN; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; ATADENOVIRUS; BACTERIAL STRAIN; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; EX VIVO STUDY; EXPRESSION VECTOR; FEMALE; HETEROLOGOUS EXPRESSION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; IMMUNOREACTIVITY; IMMUNOSTIMULATION; MACACA; MEMORY T LYMPHOCYTE; MOUSE; MYCOBACTERIUM BOVIS; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION; VACCINIA VIRUS; VIRUS IMMUNITY;

AIDS VACCINES; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; HIV INFECTIONS; HUMANS; MACACA MULATTA; MICE; MICE, INBRED BALB C; VACCINES, SYNTHETIC; VIRAL VACCINES;

ATADENOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; MUS; MYCOBACTERIUM; MYCOBACTERIUM BOVIS; MYCOBACTERIUM BOVIS BCG; OVIS; PRIMATES; VACCINIA VIRUS; VACCINIA VIRUS ANKARA;

EID: 77952736315     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02607-09     Document Type: Article

References (69)

1. Barouch, D. H., M. G. Pau, J. H. Custers, W. Koudstaal, S. Kostense, M. J. Havenga, D. M. Truitt, S. M. Sumida, M. G. Kishko, J. C. Arthur, B. Korioth-Schmitz, M. H. Newberg, D. A. Gorgone, M. A. Lifton, D. L. Panicali, G. J. Nabel, N. L. Letvin, and J. Goudsmit. 2004. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol. 172:6290-6297.
2. Both, G. W. 2004. Ovine atadenovirus: a review of its biology, biosafety profile and application as a gene delivery vector. Immunol. Cell Biol. 82: 189-195.
3. Both, G. W., F. Cameron, A. Collins, L. J. Lockett, and J. Shaw. 2007. Production and release testing of ovine atadenovirus vectors. Methods Mol. Med. 130:69-90.
4. Brandt, L., Y. A. Skeiky, M. R. Alderson, Y. Lobet, W. Dalemans, O. C. Turner, R. J. Basaraba, A. A. Izzo, T. M. Lasco, P. L. Chapman, S. G. Reed, and I. M. Orme. 2004. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect. Immun. 72:6622-6632.
5. Bridgeman, A., Y. Roshorm, L. J. Lockett, Z. Z. Xu, R. Hopkins, J. Shaw, G. W. Both, and T. Hanke. 2010. Ovine atadenovirus, a novel and highly immunogenic vector in prime-boost studies of a candidate HIV-1 vaccine. Vaccine 28:474-483.
6. Buchbinder, S. P., D. V. Mehrotra, A. Duerr, D. W. Fitzgerald, R. Mogg, D. Li, P. B. Gilbert, J. R. Lama, M. Marmor, C. Del Rio, M. J. McElrath, D. R. Casimiro, K. M. Gottesdiener, J. A. Chodakewitz, L. Corey, and M. N. Robertson. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881-1893.
7. Casimiro, D. R., F. Wang, W. A. Schleif, X. Liang, Z. Q. Zhang, T. W. Tobery, M. E. Davies, A. B. McDermott, D. H. O'Connor, A. Fridman, A. Bagchi, L. G. Tussey, A. J. Bett, A. C. Finnefrock, T. M. Fu, A. Tang, K. A. Wilson, M. Chen, H. C. Perry, G. J. Heidecker, D. C. Freed, A. Carella, K. S. Punt, K. J. Sykes, L. Huang, V. I. Ausensi, M. Bachinsky, U. Sadasivan-Nair, D. I. Watkins, E. A. Emini, and J. W. Shiver. 2005. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J. Virol. 79:15547-15555.
8. Cayabyab, M. J., B. Korioth-Schmitz, Y. Sun, A. Carville, H. Balachandran, A. Miura, K. R. Carlson, A. P. Buzby, B. F. Haynes, W. R. Jacobs, and N. L. Letvin. 2009. Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses. J. Virol. 83:5505-5513.
9. Chege, G. K., R. Thomas, E. G. Shephard, A. Meyers, W. Bourn, C. Williamson, J. Maclean, C. M. Gray, E. P. Rybicki, and A. L. Williamson. 2009. A prime-boost immunisation regimen using recombinant BCG and Pr55(gag) virus-like particle vaccines based on HIV type 1 subtype C successfully elicits Gag-specific responses in baboons. Vaccine 27:4857-4866.
10. Dorrell, L., H. Yang, A. K. Iversen, C. Conlon, A. Suttill, M. Lancaster, T. Dong, I. Cebere, A. Edwards, S. Rowland-Jones, T. Hanke, and A. J. Mc-Michael. 2005. Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine. AIDS 19:1321-1323. (Pubitemid 41224902)
11. Dorrell, L., H. Yang, B. Ondondo, T. Dong, K. di Gleria, A. Suttill, C. Conlon, D. Brown, P. Williams, P. Bowness, N. Goonetilleke, T. Rostron, S. Rowland-Jones, T. Hanke, and A. J. McMichael. 2006. Expansion and diversification of HIV-1-specific T cells following immunisation of HIV-1-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 gag vaccine. J. Virol. 80:4705-4716.
12. Douek, D. C., M. R. Betts, J. M. Brenchley, B. J. Hill, D. R. Ambrozak, K. L. Ngai, N. J. Karandikar, J. P. Casazza, and R. A. Koup. 2002. A novel approach to the analysis of specificity, clonality, and frequency of HIV-specific T cell responses reveals a potential mechanism for control of viral escape. J. Immunol. 168:3099-3104.
13. Edelman, R., K. Palmer, K. G. Russ, H. P. Secrest, J. A. Becker, S. A. Bodison, J. G. Perry, A. R. Sills, A. G. Barbour, C. J. Luke, M. S. Hanson, C. K. Stover, J. E. Burlein, G. P. Bansal, E. M. Connor, and S. Koenig. 1999. Safety and immunogenicity of recombinant bacille Calmette-Guerin (rBCG) expressing Borrelia burgdorferi outer-surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine. Vaccine 17:904-919. (Pubitemid 29074745)
14. Goonetilleke, N., S. Moore, L. Dally, N. Winstone, N. Mahmoud, I. Cebere, S. Pinheiro, G. Gillespie, D. Brown, V. Loach, J. Roberts, A. Guimaraes-Walker, P. Hayes, K. Loughran, C. Smith, P. Fast, L. Dorrell, T. Hanke, and A. McMichael. 2006. Prime-boost vaccination with recombinant DNA and MVA expressing HIV-1 clade A gag and immunodominant CTL epitopes induces multifunctional HIV-1-specific T cells in healthy subjects. J. Virol. 80:4717-4728.
15. Greenaway, H. Y., M. Kurniawan, D. A. Price, D. C. Douek, M. P. Davenport, and V. Venturi. 2009. Extraction and characterization of the rhesus macaque T-cell receptor beta-chain genes. Immunol. Cell Biol. 87:546-553.
16. Grode, L., P. Seiler, S. Baumann, J. Hess, V. Brinkmann, A. Nasser Eddine, P. Mann, C. Goosmann, S. Bandermann, D. Smith, G. J. Bancroft, J. M. Reyrat, D. van Soolingen, B. Raupach, and S. H. Kaufmann. 2005. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J. Clin. Invest. 115:2472-2479.
17. Hanke, T. 2008. STEP trial and HIV-1 vaccines inducing T-cell responses. Expert Rev. Vaccines 7:303-309. (Pubitemid 351520018)
18. Hanke, T., C. Barnfield, E. G.-T. Wee, L. Ågren, R. V. Samuel, N. Larke, and P. Liljeström. 2003. Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine. J. Gen. Virol. 84:361-368.
19. Hanke, T., T. J. Blanchard, J. Schneider, C. M. Hannan, M. Becker, S. C. Gilbert, A. V. S. Hill, G. L. Smith, and A. McMichael. 1998. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 16:439-445. (Pubitemid 28044161)
20. Hanke, T., N. Goonetilleke, A. J. McMichael, and L. Dorrell. 2007. Clinical experience with plasmid DNA- and modified vaccinia vaccine Ankara (MVA)-vectored HIV-1 clade A vaccine inducing T cells. J. Gen. Virol. 88:1-12.
21. Hanke, T., and A. J. McMichael. 2000. Design and construction of an ex-perimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat. Med. 6:951-955.
22. Hanke, T., V. C. Neumann, T. J. Blanchard, M. Becker, P. Sweeney, A. V. S. Hill, G. L. Smith, and A. McMichael. 1999. Effective induction of HIV-specific CTL by multi-epitope DNA using a gene gun in a combined vaccination regime. Vaccine 17:589-596.
23. Hanke, T., R. V. Samuel, T. J. Blanchard, V. C. Neumann, T. M. Allen, J. E. Boyson, A. S. Sharpe, N. Cook, G. L. Smith, D. I. Watkins, M. P. Cranage, and A. McMichael. 1999. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J. Virol. 73:7524-7532.
24. Hanke, T., P. Szawlowski, and R. E. Randall. 1992. Construction of solid matrix-antibody-antigen complexes containing simian immunodeficiency virus p27 using tag-specific monoclonal antibody and tag-linked antigen. J. Gen. Virol. 73:653-660.
25. Hess, J., D. Miko, A. Catic, V. Lehmensiek, D. G. Russell, and S. H. Kaufmann. 1998. Mycobacterium bovis Bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes. Proc. Natl. Acad. Sci. U. S. A. 95: 5299-5304.
26. Hofmann, C., P. Loser, G. Cichon, W. Arnold, G. W. Both, and M. Strauss. 1999. Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo. J. Virol. 73:6930-6936. (Pubitemid 29327876)
27. Honeyborne, I., A. Prendergast, F. Pereyra, A. Leslie, H. Crawford, R. Payne, S. Reddy, K. Bishop, E. Moodley, K. Nair, M. van der Stok, N. McCarthy, C. M. Rousseau, M. Addo, J. I. Mullins, C. Brander, P. Kiepiela, B. D. Walker, and P. J. Goulder. 2007. Control of human immunodeficiency virus type 1 is associated with HLA-B*13 and targeting of multiple gag-specific CD8+ T-cell epitopes. J. Virol. 81:3667-3672. (Pubitemid 46456679)
28. Hovav, A. H., M. J. Cayabyab, M. W. Panas, S. Santra, J. Greenland, R. Geiben, B. F. Haynes, W. R. Jacobs, Jr., and N. L. Letvin. 2007. Rapid memory CD8+ T-lymphocyte induction through priming with recombinant Mycobacterium smegmatis. J. Virol. 81:74-83.
29. Hryniewicz, A., D. A. Price, M. Moniuszko, A. Boasso, Y. Edghill-Spano, S. M. West, D. Venzon, M. Vaccari, W. P. Tsai, F. Tryniszewska, J. Nacsa, F. Villinger, A. A. Ansari, C. J. Trindade, M. Morre, D. Brooks, P. Arlen, H. J. Brown, C. M. Kitchen, J. A. Zack, D. C. Douck, G. M. Shearer, M. G. Lewis, R. A. Koup, and G. Franchini. 2007. Interleukin 15 but not interleukin abrogates vaccine-induced decrease in virus level in simian immunodeficiency virus mac251 infected macaques. J. Immunol. 178:3492-3504. (Pubitemid 46417614)
30. + T cells by a 4-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques. Eur. J. Immunol. 36:2574-2584.
31. Im, E. J., and T. Hanke. 2007. Short communication: preclinical evaluation of candidate HIV type 1 vaccines in inbred strains and an outbred stock of mice. AIDS Res. Hum. Retroviruses 23:857-862.
32. Im, E. J., N. Saubi, G. Virgili, C. Sander, D. Teoh, J. M. Gatell, H. McShane, J. Joseph, and T. Hanke. 2007. Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding. J. Virol. 81:9408-9418. (Pubitemid 47311483)
33. Jones, S., K. Preiter, and D. A. Portnoy. 1996. Conversion of an extracellular cytolysin into a phagosome-specific lysin which supports the growth of an intracellular pathogen. Mol. Microbiol. 21:1219-1225.
34. Joseph, J., N. Saubi, E. Pezzat, and J. M. Gatell. 2006. Progress towards an HIV vaccine based on recombinant bacillus Calmette-Guerin: failures and challenges. Expert Rev. Vaccines 5:827-838. (Pubitemid 46021059)
35. Kiepiela, P., K. Ngumbela, C. Thobakgale, D. Ramduth, I. Honeyborne, E. Moodley, S. Reddy, C. de Pierres, Z. Mncube, N. Mkhwanazi, K. Bishop, M. van der Stok, K. Nair, N. Khan, H. Crawford, R. Payne, A. Leslie, J. Prado, A. Prendergast, J. Frater, N. McCarthy, C. Brander, G. H. Learn, D. Nickle, C. Rousseau, H. Coovadia, J. I. Mullins, D. Heckerman, B. D. Walker, and P. Goulder. 2007. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13:46-53.
36. Larke, N., E.-J. Im, R. Wagner, C. Williamson, A.-L. Williamson, A. J. McMichael, and T. Hanke. 2007. Combined single-clade candidate HIV-1 vaccines induce T cell responses limited by multiple forms of in vivo immune interference. Eur. J. Immunol. 37:566-577.
37. Larke, N., A. Murphy, C. Wirblich, D. Teoh, M. J. Estcourt, A. J. McMichael, P. Roy, and T. Hanke. 2005. Induction of human immunodeficiency virus type 1-specific T cells by a bluetongue virus tubule-vectored vaccine primere-combinant modified virus Ankara boost regimen. J. Virol. 79:14822-14833. (Pubitemid 41636280)
38. Lee, M. H., L. Pascopella, W. R. Jacobs, Jr., and G. F. Hatfull. 1991. Site-specific integration of mycobacteriophage L5: integration-proficient vectors for Mycobacterium smegmatis, Mycobacterium tuberculosis, and bacille Calmette-Guerin. Proc. Natl. Acad. Sci. U. S. A. 88:3111-3115.
39. Li, S., M. Rodrigues, D. Rodriguez, J. R. Rodriguez, M. Esteban, P. Palese, S. R. Nussenzweig, and F. Zavala. 1993. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc. Natl. Acad. Sci. U. S. A. 90:5214-5218.
40. Lugosi, L., W. Jacobs, and B. R. Bloom. 1989. Transformation of BCG with plasmid DNA. Acta Leprol. 7(Suppl. 1):256-257.
41. McElrath, M. J., S. C. De Rosa, Z. Moodie, S. Dubey, L. Kierstead, H. Janes, O. D. Defawe, D. K. Carter, J. Hural, R. Akondy, S. P. Buchbinder, M. N. Robertson, D. V. Mehrotra, S. G. Self, L. Corey, J. W. Shiver, and D. R. Casimiro. 2008. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372:1894-1905.
42. McShane, H., A. A. Pathan, C. R. Sander, S. M. Keating, S. C. Gilbert, K. Huygen, H. A. Fletcher, and A. V. Hill. 2004. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med. 10:1240-1244.
43. Mercado, R., S. Vijh, S. E. Allen, K. Kerksiek, I. M. Pilip, and E. G. Pamer. 2000. Early programming of T cell populations responding to bacterial infection. J. Immunol. 165:6833-6839. (Pubitemid 32001151)
44. Miller, M. D., H. Yamamoto, A. L. Hughes, D. I. Watkins, and N. L. Letvin. 1991. Definition of an epitope and MHC class I molecule recognized by gag-specific cytotoxic T lymphocytes in SIVmac-infected rhesus monkeys. J. Immunol. 147:320-329.
45. Moniuszko, M., D. Bogdan, R. Pal, D. Venzon, L. Stevceva, J. Nacsa, E. Tryniszewska, Y. Edghill-Smith, S. M. Wolinsky, and G. Franchini. 2005. Correlation between viral RNA levels but not immune responses in plasma and tissues of macaques with long-standing SIVmac251 infection. Virology 333:159-168. (Pubitemid 40222199)
46. Mwau, M., I. Cebere, J. Sutton, P. Chikoti, N. Winstone, E. G.-T. Wee, T. Beattie, Y.-H. Chen, L. Dorrel, H. McShane, C. Schmidt, M. Brooks, S. Patel, J. Roberts, C. Conlon, S. Rowland-Jones, J. Bwayo, A. J. McMichael, and T. Hanke. 2004. An HIV-1 clade A vaccine in clinical trials: stimulation of HIV-specific T cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J. Gen. Virol. 85:911-919.
47. Mwau, M., A. J. McMichael, and T. Hanke. 2002. Design and validation of an ELISPOT assay for use in clinical trials of candidate HIV vaccines. AIDS Res. Hum. Retroviruses 18:611-618.
48. Nkolola, J. P., E. G.-T. Wee, E.-J. Im, C. P. Jewell, N. Chen, X.-N. Xu, A. J. McMichael, and T. Hanke. 2004. Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa. Gene Ther. 11:1068-1080.
49. Nordstrom, E. K., M. N. Forsell, C. Barnfield, E. Bonin, T. Hanke, M. Sundstrom, G. B. Karlsson, and P. Liljestrom. 2005. Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1. J. Gen. Virol. 86:349-354.
50. Pantelic, R. S., L. J. Lockett, R. Rothnagel, B. Hankamer, and G. W. Both. 2008. Cryoelectron microscopy map of Atadenovirus reveals cross-genus structural differences from human adenovirus. J. Virol. 82:7346-7356.
51. Price, D. A., T. E. Asher, N. A. Wilson, M. C. Nason, J. M. Brenchley, I. S. Metzler, V. Venturi, E. Gostick, P. K. Chattopadhyay, M. Roederer, M. P. Davenport, D. I. Watkins, and D. C. Douek. 2009. Public clonotype usage identifies protective Gag-specific CD8+ T cell responses in SIV infection. J. Exp. Med. 206:923-936.
52. Price, D. A., S. M. West, M. R. Betts, L. E. Ruff, J. M. Brenchley, D. R. Ambrozak, Y. Edghill-Smith, M. J. Kuroda, D. Bogdan, K. Kunstman, N. L. Letvin, G. Franchini, S. M. Wolinsky, R. A. Koup, and D. C. Douek. 2004. T cell receptor recognition motifs govern immune escape patterns in acute SIV infection. Immunity 21:793-803.
53. Rolland, M., D. Heckerman, W. Deng, C. M. Rousseau, H. Coovadia, K. Bishop, P. J. Goulder, B. D. Walker, C. Brander, and J. I. Mullins. 2008. Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads. PLoS One 3:e1424. (Pubitemid 351223225)
54. a.Rosario, M., A. Bridgeman, E. D. Quakkelaar, M. F. Quigley, B. J. Hill, M. L. Knudsen, V. Ammendola, K. Ljungberg, N. Borthwick, E.-J. Im, A. J. McMichael, J. W. Drijfhout, H. Y. Greenaway, V. Venturi, D. C. Douek, S. Colloca, P. Liljeström, A. Nicosia, D. A. Price, C. J. M. Melief, and T. Hanke. Long peptides induce polyfunctional T cells against conserved regions of HIV with superior breadth to single-gene vaccines in macaques. Eur. J. Immunol., in press.
55. Schneider, J., S. C. Gilbert, T. J. Blanchard, T. Hanke, K. J. Robson, C. M. Hannan, M. Becker, R. Sinden, G. L. Smith, and A. V. S. Hill. 1998. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4:397-402.
56. Slyker, J. A., B. L. Lohman, D. A. Mbori-Ngacha, M. Reilly, E. G. Wee, T. Dong, A. J. McMichael, S. L. Rowland-Jones, T. Hanke, and G. John-Stewart. 2005. Modified vaccinia Ankara expressing HIVA antigen stimulates HIV-1-specific CD8 T cells in ELISpot assays of HIV-1 exposed infants. Vaccine 23:4711-4719.
57. Someya, K., D. Cecilia, Y. Ami, T. Nakasone, K. Matsuo, S. Burda, H. Yamamoto, N. Yoshino, M. Kaizu, S. Ando, K. Okuda, S. Zolla-Pazner, S. Yamazaki, N. Yamamoto, and M. Honda. 2005. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guerin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif. J. Virol. 79:1452-1462. (Pubitemid 40459092)
58. Sun, R., Y. A. Skeiky, A. Izzo, V. Dheenadhayalan, Z. Imam, E. Penn, K. Stagliano, S. Haddock, S. Mueller, J. Fulkerson, C. Scanga, A. Grover, S. C. Derrick, S. Morris, D. M. Hone, M. A. Horwitz, S. H. Kaufmann, and J. C. Sadoff. 2009. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 27:4412-4423.
59. Takahashi, H., J. Cohen, A. Hosmalin, K. B. Cease, R. Houghten, J. L. Cornette, C. DeLisi, B. Moss, R. N. Germain, and J. A. Berzofsky. 1988. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility molecule-restricted murine cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 85:3105-3109.
60. Takahashi, H., Y. Nakagawa, K. Yokomuro, and J. A. Berzofsky. 1993. Induction of CD8+ cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. Int. Immunol. 5:849-857.
61. van Faassen, H., M. Saldanha, D. Gilbertson, R. Dudani, L. Krishnan, and S. Sad. 2005. Reducing the stimulation of CD8+ T cells during infection with intracellular bacteria promotes differentiation primarily into a central (CD62LhighCD44high) subset. J. Immunol. 174:5341-5350.
62. van Stipdonk, M. J., G. Hardenberg, M. S. Bijker, E. E. Lemmens, N. M. Droin, D. R. Green, and S. P. Schoenberger. 2003. Dynamic programming of CD8+ T lymphocyte responses. Nat. Immunol. 4:361-365.
63. Verreck, F. A., R. A. Vervenne, I. Kondova, K. W. van Kralingen, E. J. Remarque, G. Braskamp, N. M. van der Werff, A. Kersbergen, T. H. Ottenhoff, P. J. Heidt, S. C. Gilbert, B. Gicquel, A. V. Hill, C. Martin, H. McShane, and A. W. Thomas. 2009. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS One 4:e5264.
64. Wee, E. G.-T., S. Patel, A. J. McMichael, and T. Hanke. 2002. A DNA/MVAbased candidate HIV vaccine for Kenya induces multi-specific T cell responses in rhesus macaques. J. Gen. Virol. 83:75-80.
65. WHO. 2007. Application of revised BCG recommendations. Wkly. Epidemiol. Rec. 82:195-196.
66. Winstone, N., A. Guimarães-Walker, J. Roberts, D. Brown, V. Loach, N. Goonetilleke, T. Hanke, and A. J. McMichael. 2009. Increased detection of proliferating, polyfunctional, HIV-1-specific T cells in DNA-MVA vaccinated human volunteers by cultured IFN-γ ELISPOT assay. Eur. J. Immunol. 39:975-985.
67. Yang, H., T. Dong, E. Turnbull, S. Ranasinghe, B. Ondondo, N. Goonetilleke, N. Winstone, K. di Gleria, P. Bowness, C. Conlon, P. Borrow, T. Hanke, A. McMichael, and L. Dorrell. 2007. Broad TCR usage in functional HIV-1-specific CD8+ T cell expansions driven by vaccination during highly active antiretroviral therapy. J. Immunol. 179:597-606. (Pubitemid 46986577)
68. Yasutomi, Y., S. Koenig, S. S. Haun, C. K. Stover, R. K. Jackson, P. Conard, A. J. Conley, E. A. Emini, T. R. Fuerst, and N. L. Letvin. 1993. Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys. J. Immunol. 150:3101-3107. (Pubitemid 23127560)
69. Yu, J. S., J. W. Peacock, S. Vanleeuwen, T. Hsu, W. R. Jacobs, Jr., M. J. Cayabyab, N. L. Letvin, R. Frothingham, H. F. Staats, H. X. Liao, and B. F. Haynes. 2006. Generation of mucosal anti-human immunodeficiency virus type 1 T-cell responses by recombinant Mycobacterium smegmatis. Clin. Vaccine Immunol. 13:1204-1211.